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Abstract
In Alzheimer Disease (AD), the mechanistic connection of the two major pathological hallmarks, namely deposition
of Amyloid-beta (Aβ) in the form of extracellular plaques, and the pathological changes of the intracellular protein
Tau (such as phosphorylation, missorting, aggregation), is not well understood. Genetic evidence from AD and
Down Syndrome (Trisomy 21), and animal models thereof, suggests that aberrant production of Aβ is upstream of
Tau aggregation, but also points to Tau as a critical effector in the pathological process. Yet, the cascade of events
leading from increased levels of Aβ to Tau-dependent toxicity remains a matter of debate.
Using primary neurons exposed to oligomeric forms of Aβ, we have found that Tau becomes mislocalized (missorted)
into the somatodendritic compartment. Missorting of Tau correlates with loss of microtubules and downstream
consequences such as loss of mature spines, loss of synaptic activity, and mislocalization of mitochondria.
In this cascade, missorting of Tau induces mislocalization of TTLL6 (Tubulin-Tyrosine-Ligase-Like 6) into the dendrites.
TTLL6 induces polyglutamylation of microtubules, which acts as a trigger for spastin mediated severing of dendritic
microtubules. Loss of microtubules makes cells unable to maintain transport of mitochondria, which in turn results in
synaptic dysfunction and loss of mature spines. These pathological changes are absent in TauKO derived primary
neurons. Thus, Tau mediated mislocalization of TTLL6 and spastin activation reveals a pathological gain of function for
Tau and spastin in this cellular model system of AD.
In contrast, in hereditary spastic paraplegia (HSP) caused by mutations of the gene encoding spastin (spg4 alias SPAST),
spastin function in terms of microtubule severing is decreased at least for the gene product of the mutated allele,
resulting in overstable microtubules in disease model systems. Whether total spastin severing activity or microtubule
stability in human disease is also affected is not yet clear. No human disease has been associated so far with the long-
chain polyglutamylation enzyme TTLL6, or the other TTLLs (1,5,11) possibly involved.
Here we review the findings supporting a role for Tau, spastin and TTLL6 in AD and other tauopathies, HSP and
neurodegeneration, and summarize possible therapeutic approaches for AD and HSP.
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Background
In Alzheimer Disease (AD), one observes two major ag-
gregating proteins: Amyloid-beta (Aβ), which accumulates
in the form of plaques mainly in the extracellular space
and the microtubule associated protein Tau, which aggre-
gates in the form of paired helical filaments (PHFs) intra-
cellularly [59]. The connection of these two major
pathological hallmarks is not well understood. Evidence
from AD, Down Syndrome (Trisomy 21), and from corre-
sponding animal models, indicates that aberrant produc-
tion of Aβ is upstream of Tau pathology. In genetic cases
of AD, Aβ deposition precedes Tau aggregation. Addition-
ally, there is no Tau mutation that causes AD or even in-
creases the risk of getting AD. Genetic cases of AD cause
a net increase in Aβ production or a shift in the isoform
ratio towards more aggregation prone forms of Aβ, or in-
crease the aggregation propensity of Aβ itself, as in the
case of the arctic mutation [2, 23, 39, 49]. Conversely, a
mutation that decreases the aggregation capacity of Aβ is
protective of AD [33].
Nonetheless, Tau aggregates, but not Aβ-plaque burden,
correlate with synaptic loss and cognitive decline in AD
patients [7]. Also, Tau-knockout (TauKO) protects from
AD-like pathologies in several models of AD [30, 54, 78].
Despite the fact that there is no genetic association of Tau
with AD, mutations of Tau cause different forms of neuro-
degenerative disease (e.g. Frontotemporal Dementia with
Parkinsonism linked to Chromosome 17 (FTDP-17) [29,
51]), or increase the risk for FTD-spectrum disorders [40].
Tau pathology is also an important part of many other
neurodegenerative diseases (FTLD-Tau, Parkinsonism,
ALS, PSP, Tangle-only dementia, CTE etc.; for review see
[15, 65]). These observations point to Tau as a critical
effector in pathological processes.
Like Tau, spastin is an important regulator for micro-
tubule dynamics. In contrast to Tau, which stabilizes
microtubules, spastin’s main function is to sever microtu-
bules. Thereby spastin either reduces microtubule mass,
generating short microtubules for the seeding of new mi-
crotubules, or facilitates translocation of microtubules.
Mutations of spastin causing Hereditary Spastic Paraplegia
(HSP) often compromise the severing ability of spastin,
which is considered a loss of function effect. However,
microtubule binding of spastin often is unaffected by these
mutations. Spastin therefore might bind and bundle mi-
crotubules, which can be considered a pathological gain of
function (for review on SPAST caused HSP see [61]).
We recently discovered a pathological cascade that in-
volves missorting of the axonal microtubule associated
protein Tau (MAPT) into the somatodendritic compart-
ment of neurons. This causes mislocalization of TTLL6
into dendrites, polyglutamylation of microtubules, and
finally microtubule severing of dendritic microtubules by
spastin. The implication of this pathological cascade for
AD, FTLD, HSP, and other forms of neurodegeneration
is not clear. Here we summarize possible ties and differ-
ences of Tau and spastin action in neurodegeneration,
and outline possible therapeutic approaches.
Review
The pathological cascade: from Amyloid-β exposure via
Tau missorting to spastin activation
To elucidate the pathological cascade leading to neurode-
generation in AD, we established a system to model the
effects of Aβ on Tau. In mature rodent primary neurons,
Tau is present in several isoforms, is sorted into the axon
and excluded from the somatodendritic compartment, all
of which is similar to the adult human brain. To trigger
AD-like pathological changes of Tau, we exposed primary
neurons to a pre-aggregation form of Aβ (oligomeric Aβ),
which is thought to be the toxic trigger in AD [3, 24, 35].
We investigated changes of Tau and related cellular path-
ologies using biochemical methods, fluorescence micros-
copy including live cell imaging, and electron microscopy.
After exposure to oligomeric Aβ, Tau becomes mislocal-
ized (missorted) into the somatodendritic compartment, a
feature reminiscent of incipient AD [5]. Interestingly, the
missorted Tau does not originate from the axon, but is
newly synthesized, fails to become sorted into the axon,
and instead spreads throughout the somatodendritic com-
partment. Missorting of Tau correlates with a loss of
synapses, most pronounced in dendrites containing high
amounts of Tau [81]. This provides a link between the
mislocalization of Tau and the cognitive decline observed
in mouse models of AD and in AD patients. One of the
key features is a dramatic loss of microtubules in neurons
with missorted Tau [80]. Microtubules are of great im-
portance as tracks of the intracellular traffic system based
on microtubule-dependent motor proteins. This is par-
ticularly so for neurons whose extended processes require
highly efficient transport.
Treatment of neurons with Aβ oligomers leads to mis-
sorting of Tau into dendrites, with subsequent decay of
microtubules and mature spines (Fig. 1a, b, c). Conse-
quently, mitochondria, vesicles, and other cargo suffer from
traffic jams in these dendrites. Neurofilaments that are usu-
ally transported along microtubules from the soma into the
axon, become also mislocalized to the somatodendritic
compartment, which indicates impaired transport.
Most of these pathological changes depend on the pres-
ence of Tau, as in neurons derived from Tau knockout
mice (TauKO), loss of microtubules and synapses, aber-
rant mitochondria and neurofilament distribution do not
occur [78].
In search for the causes of microtubule breakdown in
dendrites, we found that the decay of microtubules is exe-
cuted by spastin, a microtubule severing enzyme. Spastin in
turn is recruited to microtubules by polyglutamylation of
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Fig. 1 (See legend on next page.)
Zempel and Mandelkow Molecular Neurodegeneration  (2015) 10:68 Page 3 of 12
microtubules, conferred by the enzyme TTLL6 (Tubulin-
Tyrosin-Ligase-Like-6) and possibly related isoforms.
TTLL6 is a microtubule modifying ligase which catalyzes
the addition of polyGlu residues to Glu residues near the
C-terminal tail of α-tubulin. This highly acidic configur-
ation leads to the recruitment of the microtubule severing
protein spastin and subsequent destruction of microtu-
bules. TTLL6 is mislocalized from the soma into dendrites
by a Tau dependent mechanism, likely involving an inter-
action of TTLL6 with the N-terminal half of Tau [78]
(Fig. 1d) [38].
Normal spastin levels seem to be essential for the micro-
tubule breakdown induced by Tau missorting and Aβ-
exposure. In control neurons, Aβ exposure leads to micro-
tubule destruction, while knockdown of spastin via
shRNA results in stable microtubules in spite of Aβ ex-
posure (Fig. 2a). Of note, once the toxic stimulus of Aβ-
oligomers disappears, microtubule density recovers,
implying that without constant or repetitive exposure to
toxic, oligomeric forms of Aβ, spastin over-activity returns
to baseline levels without further intervention [78]. Thus,
spastin is the effector of microtubule breakdown in this
cell culture model of Alzheimer disease (Fig. 2b). The flip
side of the spastin coin is the suggested mechanisms of
HSP, where mutant or absent spastin activity impairs nor-
mal microtubule dynamics (see below), which results in
bundled and overstable microtubules (Fig. 2c) [32].
Apart from the scenario described above, Tau has been
implicated in several ways in the impairment of microtu-
bules and synapses. Along with the related proteins MAP2
and MAP4, Tau belongs to the class of "structural MAPs"
capable of binding to and stabilizing microtubules. Proper
axonal sorting of Tau depends on intact Tau-microtubule
interactions [34]. In the pathological condition of Tau mis-
sorting, however, Tau is altered by posttranslational modi-
fications, notably phosphorylation at a number of sites
(See figure on previous page.)
Fig. 1 Aβ oligomers induce missorting of Tau into dendrites. Missorting of Tau correlates with dendritic loss of microtubules and mislocalization
of TTLL6. a, b Micrographs of fluorescently stained primary hippocampal neurons aged for 21 days in vitro after treatment with Aβ oligomers. (a)
Tau is stained with an antibody against total Tau (K9JA, green color). Staining of the dendritic marker MAP2 is shown in red. In control conditions,
Tau and MAP2 do not colocalize (a1, boxed area shows a dendrite and cell body without Tau). After exposure to Aβ, Tau becomes missorted into
the somatodendritic compartment, where it then colocalizes with MAP2 (a2, boxed area shows a dendrite and cell body with Tau missorting). (b)
Staining of f-actin in dendritic segments with phalloidin. In control conditions, there are numerous spines (b1, f-actin positive dendritic protru-
sions, arrowheads). After exposure to Aβ, mature spines are lost (b2). c Microtubules were stained using an antibody against tubulin after fixing
and extracting to favor microtubules over free tubulin. The filamentous structures within the dendrite in c1 (framed by dotted lines) are microtubules. In
control conditions dendrites display dense microtubules (c1), whereas microtubules are lost after Aβ treatment (c2). Proximal parts of dendritic segments
are magnified in lower panels. cb: cell body; d: dendrites. d Brain sections from Tau transgenic mice where missorting of Tau is present, TTLL6 is mislocal-
ized to dendrites even without exposure to Aβ. Boxed areas highlight examples of dendritic segments. Adapted from [78]
Fig. 2 Spastin executes microtubule loss after invasion of dendrites by Tau and TTLL6. a Experimental evidence for spastin mediated microtubule
breakdown in a neuronal cell model of AD. Spastin was silenced using shRNA with a vector co-expressing mRFP in primary hippocampal neurons
aged 16 days in vitro. Cells were then treated with 1 μM Aβ for 3 h. Silencing of spastin results in stable microtubules after Aβ treatment. Cells expressing
shRNA show no microtubule reduction in dendrites (arrows, a1). Neighboring untransfected cells with normal spastin levels show loss of microtubules in
dendrites after Aβ treatment (a2, arrowheads). b, c Diagrams of proposed mechanisms for microtubule breakdown in AD and overstable microtubules in
HSP. (b) In Alzheimer disease and other tauopathies, spastin mediates microtubule disassembly in dendrites in the presence of missorted Tau. (c) In the
case of HSP caused by mutations of sp4/SPAST, spastin is unable to sever microtubules, but might still be able to bind them, resulting in overstable and
bundled microtubules. Modified from [32, 78]
Zempel and Mandelkow Molecular Neurodegeneration  (2015) 10:68 Page 4 of 12
[25, 48]. In contrast to low-level physiological phosphoryl-
ation, pathologically increased phosphorylation could lead
to detachment of Tau from microtubules, with subsequent
destabilization of microtubules (for discussion of physio-
logical vs. pathological phosphorylation see [1, 77, 79]).
An example is the phosphorylation of Tau at the KXGS-
motifs in the repeat domain of Tau [71, 81]. These sites
regulate the binding of Tau to microtubules and are targets
of the Microtubule-Affinity-Regulating Kinase (MARK). In
maturing neurons MARK is most active in growth cones,
in the soma and the dendrites, but not in axons [72]. When
phosphorylated at the KXGS-motifs, Tau cannot bind and
stabilize microtubules, and can become missorted [43].
This in turn can lead to abberant interactions of mis-
sorted Tau with proteins in the somatodendritic compart-
ment, e.g. the tyrosine kinase Fyn [30].
Tau has been shown to protect microtubules against
attack by another microtubule severing protein, katanin
[52]. Thus, detachment of Tau from microtubules as a
result of Tau phosphorylation could further promote
the destabilization of microtubules, either by lack of
stabilization and/or by loss of protection against severing.
Tau would then also be free to translocalize into spines and
mediate the loss of synapses, as shown by experiments
using pseudophosphorylated or mutated Tau [28, 78]. The
precise mechanism of how phosphorylated Tau induces loss
of mature spines and loss of f-actin in spines is unclear.
Suggested mechanisms circle around a NMDA-receptor
mediated calcium rise, as glutamate triggers similar patho-
logical effects [81]. For example, NMDA-receptors could
be released from the synapse to the dendritic shaft after
f-actin disassembly mediated by phosphorylated Tau. This
would cause long term depression and excitotoxicity, pos-
sibly by a calcineurin dependend mechanism [30, 57, 74, 79].
Spastin activation in AD vs. spastin inactivity in HSP
Mutations in the gene encoding spastin –SPAST– are the
single most common cause of autosomal dominant her-
editary spastic paraplegia (HSP) and cause about 40 % of
familial HSP and about 20 % of sporadic HSP (for recent
review on HSP see [21]). Spastin protein occurs in four
isoforms (Fig. 3a), depending on alternative splicing of
exon 4 and an alternative translation initiation codon, but
the predominant isoforms are of 60 and 68 kDa size [11].
Spastin has diverse cellular functions. They include mem-
brane shaping and membrane trafficking, but the best
known function is microtubule severing. Spastin consists of
two main structural domains (Fig. 3a): (i) a microtubule
interacting and transport (MIT) domain at the N-terminus,
and (ii) an AAA-ATPase domain at the C-terminus, which
is responsible for microtubule severing (Fig. 3b). Attached
to the AAA-ATPase domain is the microtubule binding do-
main (MTBD), thus spastin has two domains interacting
with microtubules. Near the N-terminus there is also a
transmembrane (TM) domain possibly involved in ER
shaping and trafficking. Only the full length isoform (M1)
with 616aa contains the TM domain, while the slightly
shorter isoform M87 (M85 in rodents, hereafter referred to
as M87), lacks the highly hydrophobic 86 N-terminal aa,
which include the TM domain [11].
In HSP with SPAST mutations the MT-severing activity
of spastin is decreased: Over 300 pathological mutations,
including partial deletions, have been described, mostly in
the AAA-ATPase domain [60]. In SPAST related HSP, hap-
loinsufficiency of spastin results in impaired microtubule
severing and as such represents a loss of function pheno-
type. As the MIT or the MTBD domain in HSP-patients is
still intact, spastin mutants can still bind to and crosslink
microtubules, which could result in bundles of stable mi-
crotubules [62]. This represents a gain of pathologic func-
tion (see below).
Thus, in a formal sense, the view that microtubule
severing by spastin might be impaired in HSP (i.e. under-
activity of spastin) is the opposite to our proposed patho-
logical cascade of AD, which involves aberrant micro-
tubule breakdown by spastin (i.e. over-activity of spastin;
Fig. 2b, c, Fig. 3c). Under- and over-activity of spastin are
the two sides of the same coin, both leading to neurode-
generation. In the following sections, we will explore com-
mon mechanisms and potential therapeutic avenues.
Triggering spastin activity: roles for TTLLs
Spastin is recruited to microtubules by polyglutamylation,
a specific type of posttranslational modification of micro-
tubules [38]. Accordingly, we found that the polyglutamy-
lation of microtubules precedes Aβ-induced microtubule
loss. Tau appears to mediate the activation of spastin
(=microtubule severing) via recruitment of TTLL6. Tau is
necessary for an enrichement of TTLL6 into dendrites,
where TTLL6 then catalyzes the ligation of polyGlu resi-
dues within the C-terminal tail of α-tubulin.
Polyglutamylation can also be induced by other members
of the Tubulin-Tyrosin-Ligase-Like family, in particular
TTLL1, 4, 5, 6, 7, 11, and 13 [31]]. Of these, mainly TTLL1,
4, 5 and 7 initiate polyglutamylation with different prefer-
ences for α-tubulin and β-tubulin. The main glutamylation
sites are on Glu445 of α-tubulin (type A1A/B), and on
Glu435 of β-tubulin (type B2A/B, Glu438 for B3-tubulin),
but several other sites are possible due to the high glutam-
ate content of the acidic C-terminal tail of tubulin [31].
TTLL4 or 7 catalyze the ligation of further Glu residues
to microtubules, preferentially on β-tubulin, and TTLL5
on α-tubulin. This results in branching points and short
polyGlu side chains that do not yet suffice for spastin
mediated severing of microtubules. By contrast, only
TTLL6 and 11 elongate polyGlu side chains on α-
tubulin, in a manner which initiates spastin mediated
severing [38].
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It is currently not clear whether Tau-dependent mislocali-
zation of TTLL6 in response to Aβ is the sole mediator of
microtubule loss in dendrites, or whether this can be
achieved by other TTLLs as well. Polyglutamylation of mi-
crotubules is reversible; the enzymes that are responsible
for deglutamylation have recently been identified and be-
long to the class of cytosolic carboxypeptidases (CCP). Of
these, CCP5 removes mainly branching points, while
CCP1, 4, 6 reduce the glutamate chain length [55]. Thus,
other polyglutamylases and deglutamylases could also be
involved in Aβ and Tau mediated loss of microtubules.
Tackling pathological spastin activity: therapeutic
potential for AD and HSP
The proposed mechanisms for the pathological changes in
spastin activity in HSP and in our neuronal cell model of
AD are flip sides of the same coin. In HSP and models
thereof, spastin activity is decreased, whereas in the cell
model of AD, spastin is aberrantly activated and induces
breakdown of microtubules. Consistent with this, AD pa-
tients and several model systems of tauopathy show de-
creased microtubule density (see Table 1). Thus, inhibiting
the microtubule severing activity of spastin could be bene-
ficial in an AD setting. In HSP caused by SPAST gene mu-
tations, spastin is unable to sever microtubules, but at
least some forms of mutated spastin might still bind and
cluster microtubules, resulting in overstable bundled
microtubules (see Fig. 2c for schematics). In this context,
it might be worthwhile mentioning that both spastinKO
and TauKO mice display late and moderate motor deficits
[13, 36, 41, 47, 70], possibly due to stalled microtubule-
based transport. In neurons derived from spastinKO-mice
or HSP-patients, axonal varicosities that contain organ-
elles and microtubule fragments can be observed [19, 26,
70]. Similar varicosities were also observed in axons of







Fig. 3 Spastin domain structure, and proposed mechanism of Tau mediated microtubule loss. a Domain structure of spastin. Spastin contains four main
domains: TM, transmembrane domain; MIT, microtubule interacting and transport domain, MTBD, microtubule binding domain; and AAA, ATPase
associated with various cellular activities domain. Adapted from [56, 60]. b Severing of microtubules by spastin and subsequent disassembly. MTs are
fluorescently labeled (Atto488) and stabilized by taxol. Yellow arrowheads indicate areas where microtubules are severed by spastin. Figure by courtesy of
G. Woehlke (Tech. Univ. Munich), adapted from [17]. For movies of spastin-induced severing of microtubules see [17]. c Model of Tau dependent spastin
mediated severing of microtubules: (1) Missorted Tau induces translocation of TTLL6 to dendritic microtubules. (2) Tau detaches from microtubules (i.e. has
a reduced dwell time on microtubules, possibly as a result of increased phosphorylation by MARK). (3) TTLL6 executes polyglutamylation of microtubules
which triggers the activation of spastin and severing of microtubules
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mutAPP or traumatic brain injury) were present, but
microtubule content was not investigated. Many different
conditions may lead to late and moderate motor deficits,
but this raises the question of possible shared mechanisms
of spastin and Tau action on maintaining axonal health. In
the following section we explore if and how inhibitors of
spastin or upstream regulators of spastin could be beneficial
for AD and SPAST-caused HSP.
Similar upstream mechanism of spastin recruitment in AD
and HSP: increased polyglutamylation of microtubules
The steps upstream of spastin recruitment in AD and HSP
might be similar in spite of the different outcomes: In case
of pathological severing as in the proposed model for AD,
microtubules first need to be polyglutamylated (by TTLL6
and possibly also by TTLL11 and the priming ligases
TTLL1/5) [38]. In case of aberrant microtubule bundling
and impaired severing as proposed for HSP, polyglutamyla-
tion still might be necessary to guide the severing-deficient
spastin to microtubules, but this question has not yet been
addressed experimentally. Thus, targeting binding of spas-
tin to microtubules, or microtubule polyglutamylation by
TTLL1, 5, 6 or 11 could be a therapeutic option not just
for AD and other tauopathies, but also for SPAST caused
HSP.
Pathological gain of function of spastin in HSP: potential
benefits of spastin inhibition in HSP
Most mutations of spastin are present within the AAA-
ATPase domain and lead to a loss of microtubule sever-
ing, therefore HSP caused by spastin mutation is consid-
ered a loss of function or haploinsufficiency phenotype
[60]. But loss of function of the severing activity of spas-
tin cannot explain important aspects of the disease and
observations made in model systems of HSP. There is
no correlation between spastin levels and the severity
of neurodegeneration in disease and model systems
[60, 76]. Knockout or truncation of spastin in mice only
results in late and moderate motor deficits, which are a
lot more subtle than those in human patients suffering
from HSP [36, 70].
Also, HSP linked to spastin mutation affects mainly the
corticospinal tracts without any involvement of the periph-
eral nervous system. In the central nervous system effects
are most obvious in the spinal cord. Other parts of the cen-
tral nervous system are not affected or only at later stages.
Table 1 Effects on microtubules in AD, AD models, models of tauopathy and SPAST-HSP models





AD patient study microtubule reduction - - [10]
AD model:Primary neurons
exposed to oligomeric Aβ
specific loss of dendritic
microtubules
spastin/TTLL6 mediated aberrant






AD model: Primary neurons
exposed to prefibrillar Aβ
loss of microtubules N-terminal domain of Tau
(aa 1–248)
- [37]
Tauopathy model: tg-mice with




- Epothilone D [82]
Model of HSP: tg-mice (putative KO)




axonal swellings Nocodazole, Taxol,
Vinblastine
[19, 70]
Model of HSP: patient derived
olfactory neurons
low levels of acetylated
tubulin, slow peroxisome
trafficking
- taxol, vinblastine, epothilone,
noscapine
[18]




binding of severing deficient
spastin isoform M1 to
microtubules
reduction of M1 isoform;
M85 isoform had no effect
[62, 63]




- Overexpression of spastin
isoforms M1 and M87
[26]





Model of HSP: tg-mice (putative KO) - axonal swellings, perturbed
transport
- [36]
Model of HSP: zebrafish KD of spastin impaired MT dynamics spastin function required for
physiological MT dynamics
no beneficial effect of
nocodazole
[9]
Drosophila model of axon regeneration
after axotomy in heterozygous KO and
spastin overexpression
no effect on microtubule
polarity or developmental
neuritic outgrowth
heterozygous KO of spastin
impairs axonal regeneration
overexpression of spastin
also results in impaired
axonal regeneration
[66]
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There are, however, reports of dementia and cognitive de-
cline associated with HSP, but these are very subtle, usually
below clinical thresholds, and virtually absent when com-
pared to intrafamilial controls [22, 68], but this is a matter
of debate (see e.g. [46]). There is one report on a mutation
of spastin (exon 10, R424G), in which authors also looked
for other brain pathologies and identified Lewy bodies and
tauopathy [73]. The tauopathy found corresponded to
Braak stage 2, an AD neuropathology stage which is nor-
mally not associated with dementia, but this HSP patient
did suffer from dementia [6, 73]. More human studies are
needed to test the involvement of Tau in HSP.
Because a loss of function cannot well explain many of
the phenotypes of HSP and model systems thereof, a
pathological gain of function mechanism which also
explains the spinal cord involvement has been proposed
[62, 70]. The two major isoforms of spastin resulting from
the two start codons show differential distribution and
pathology involvement in model systems. M1 is only
present in the adult spinal cord, while M87 is ubiquitous;
M1 appears to be detrimental to axonal transport and MT
dynamics, whereas M87 is not [64]. Also, in humans, sig-
nificant levels of M1 were only detected in the adult spinal
cord, not in the brain [63]. Only mutated M1, but not
M87, decorates MTs and thereby could over-stabilize
them, resulting in impaired (i.e. reduced) MT dynamics
[62]. This mechanism has only been shown for some mu-
tations, but as most of the mutations are present within
the AAA-ATPase domain, spastin would retain its ability
to bind to and bundle microtubules. Therefore, an inhibi-
tor of M1 spastin activity or M1 binding to MTs could be
of therapeutic value for at least some SPAST mutation
based cases of HSP.
Spastin has diverse cellular function apart from MT-
severing, many of which could result in a pathological
gain of function if SPAST is mutated (for review see Baas
and Solowska [61]). The M1 isoform specifically interacts
with atlastin 1, a large integralmembrane GTPase, which
mediates homotypic fusion of ER-tubules. Of note, muta-
tions of atlastin 1 are the second most common cause of
HSP [83], indicating that impaired ER-shaping along mi-
crotubules is of great importance in HSP. As most
SPAST mutations do not affect the interaction motif of
spastin for atlastin, impairment of ER-tubule shaping
could also be a toxic gain of function mechanism in HSP
independent of MT-severing. In a model system of mu-
tated atlastin 1 (encoded by ATL1, also SPG3A), how-
ever, impairments could be prevented by the use of
microtubule stability modulating drugs (vinblastine and
taxol; [84]). This indicates that also in HSP cases that are
not caused by mutation of spastin, modulation of micro-
tubule stability could be of therapeutic value, but more
studies are needed here to elucidate the molecular
pathomechanisms.
Increased spastin activity in glioblastoma
Of note, increased spastin levels have been linked to in-
creased malignancy and invasiveness of glioblastomas. Al-
though the mechanisms are unclear, increased spastin
expression resulted in the formation of protrusions and de-
creased cell proliferation of cancer cell lines. High-grade
malignancy glioblastomas were linked to increased expres-
sion of spastin. Spastin could shift cancer populations from
cancer cells showing high proliferation to cells that prolifer-
ate less, but show greater malignancy and invasiveness. This
change in properties of cancer cells results in cancers more
difficult to treat. Therefore spastin inhibitors might also be
of therapeutic value for certain forms of brain cancer [16].
Counterindications for the use of spastin inhibitors
Physiological functions of spastin might be essential for cel-
lular homeostasis, which would tamper hope of using spas-
tin as a therapeutic target. Knocking down spastin during
early stages of development results in impaired dendritic
branching and outgrowth in cell culture [53]. However,
there are no reports of developmental defects in human pa-
tients of HSP, indeed disease onset usually occurs after sev-
eral asymptomatic decades of life. Loss of spastin function
by knockout in mice only results in late and moderate
motor deficits and no developmental deficits [36, 70].
In the context of axon regeneration, it has been reported
that axotomized Drosophila sensory neurons are able to re-
generate their axon from the axon stump or the dendrite
only when spastin is present homozygously, but not when
one allele is missing. Other microtubule severing enzymes
(e.g. kat-60 (the Drosophila homologue of human katanin-
p60), kat-60 L and fidgetin) did not have an effect on axon
regeneration in case of heterozygous loss of function mu-
tants. Other microtubule related functions, such as axonal
outgrowth during development or microtubule polarity in
axons and dendrites were unaltered in the same study [66].
Thus, at least in the context of axon regeneration, lowering
spastin activity would not be beneficial.
Taken together, these notions indicate that inhibiting
spastin might not harm overall neuronal function and
thus could be beneficial for patients. If the gain of function
mechanism proves valid for HSP, inhibiting specifically the
microtubule severing function of spastin might not be of
therapeutic value for HSP patients, as this would lead to
even more MT bundling and overstabilization. For the
treatment of HSP a microtubule binding inhibitor would
be preferable, while for AD either an inhibitor of micro-
tubule severing or microtubule binding inhibitor could be
of therapeutic value. It remains unclear, however, whether
microtubule bundling by mutated spastin is an in vitro
artefact as this has not been demonstrated in vivo. Inhibit-
ing mutant spastin could be beneficial over absence of
spastin, but this has not been addressed experimentally.
Zempel and Mandelkow Molecular Neurodegeneration  (2015) 10:68 Page 8 of 12
Regulation of spastin
Apart from polyglutamylation of microtubules by TTLL6
and TTLL11 (see above), little is known about the regula-
tion of spastin activity in physiological and pathological set-
tings. PAK3 is one of the six known p21-activated kinases
(PAKs), which is part of the group I PAKs (PAK1,2,3). PAKs
can be activated by multiple signaling molecules, particu-
larly by Rho family small GTPases. In a neuronal context
PAKs regulate neurite outgrowth, spine morphology and
synaptic plasticity. Mutations in the PAK3 gene were linked
to X-linked mental retardation (for review on physiology
and pathology of PAKs see [45]). Interestingly, overexpres-
sion of PAK3 was found to enhance the Drosophila eye de-
generation phenotype induced by overexpression of spastin.
Conversely, loss of PAK3 function prevented spastin medi-
ated defects in synaptic function. This indicates a tight gen-
etic and functional interaction between spastin and PAK3
[50]. However, pharmacological manipulation of PAK3 with
effects on spastin has not yet been demonstrated.
The Notch signaling agonist Jagged1 was found to induce
increased microtubule stability, similar to low doses of the
microtubule stabilizer Taxol. Jagged1 downregulates the ex-
pression of spastin, which results in higher stability of mi-
crotubules [20]. Conversely, exposure of primary neurons
to Aβ induced the expression of the Notch antagonist
Numb, which could be counteracted by the pro-survival
Notch pathway induced by the endocannabinoids ananda-
mide and 2-arachidonoglycerol. As a Notch signaling
modulator, anandamide also shifts gamma-secretase pro-
cessing from APP to Notch1, which would also be benefi-
cial in an AD-setting ([69], see review for Notch signaling
and its influence on microtubule stabilization and synaptic
plasticity [4]).
Transcription of spastin was shown to be upregulated
by the transcription factors NRF1 and SOX11, whereas
miR-96 and miR-182 downregulate both mRNA stability
and protein levels of spastin [27].
Modulating microtubule dynamics as therapeutic
approaches for AD and HSP
For AD, tauopathy and HSP models, both microtubule sta-
bilizing and destabilizing drugs have been investigated and
reported to show beneficial effects (see e.g. [14, 18, 19], and
Table 1 for details and complete list). It is surprising that
antagonizing drugs can lead to a similar end result, i.e. res-
cue from SPAST caused defects. The underlying mecha-
nisms are unclear. Microtubule destabilizing agents used
(nocodazole, noscapine, vinblastine) might compensate for
decreased severing of mutant spastin by increasing the
amount of dynamic labile microtubules, and by increasing
microtubule mass by minus end detachment of microtu-
bules from their organizing centers [75]. Microtubule sta-
bilizing drugs (taxol, epothilone D) could rely on activation
of other microtubule severing enzymes to compensate for
decreased severing by mutant spastin. For instance, in-
creased microtubule stabilization leads to increased acetyl-
ation of microtubules, which in turn leads to increased
katanin based severing [67]. Microtubule-stabilizing drugs
such as taxol and epothilone D are used in cancer therapy,
as they overstabilize microtubules and thus induce mitotic
arrest and apoptosis of dividing cells. At lower concentra-
tions these drugs marginally stabilize microtubules just
enough to counteract microtubule destabilization in models
of AD, tauopathy and surprisingly also HSP (Table 1 and
for review [8]). However, taxol is not blood–brain barrier
penetrant and causes peripheral neuropathy, and epothi-
lone D inhibits the P-glycoprotein (Pgp)-transporter (a
widely distributed toxin/drug efflux ABC-transporter), both
of which could be responsible for undesired neurotoxicity
and/or drug-drug interaction. Other promising, non-
naturally occurring microtubule-stabilizing drugs are being
developed and tested [44].
Using microtubule stabilizing drugs for the treatment of
AD and HSP has also some caveats: Common side effects
of taxol (when used at elevated concentrations in cancer
therapy) include peripheral neuropathy, likely due to im-
pairment of microtubule based transport in the long per-
ipheral neurons (for review see [58]). As dementia patients
would have to be treated for decades, even the use of lower
concentrations of microtubule stabilizing drugs might re-
sult in similar problems.
A clinical trial for epothilone D for the treatment of
patients with mild AD was discontinued after a phase 1
trial in 2013. Also, one clinical trial aiming at micro-
tubule stabilization with Davunetide (alias Neuroactive
Peptide NAP, an eight amino acid neuropeptide) for the
treatment of neurodegeneration (such as the tauopathy
Progressive Supranuclear Palsy, PSP) was negative in all
endpoints, which prompted the halt of other studies
with the same compound for other applications (bio-
markers) and dementia (Frontotemporal lobar degener-
ation (FTLD), Corticobasal Degeneration (CBD); for
more information on ongoing and halted clinical trials
on AD see www.alzforum.org/clinical-trial-registries).
Another microtubule stabilizing drug, TPI287, a syn-
thetic taxane derivative that crosses the blood brain bar-
rier, is used in a clinical phase I safety trial for several
tauopathies (AD, CBD, PSP, and 4 Repeat Tauopathy
(4RT)) as well as different brain cancer conditions (for
more information on clinical trials of TPI287 see
www.clinicaltrials.gov).
However, indirect microtubule-stabilization via inhib-
ition of MT-severing by TTLLs and spastin (or other
microtubule severing proteins) might be more feasible as
these enzymes are present in far lower concentration than
tubulin. Very recently, the microtubule severing enzyme
fidgetin was shown to trim the growing ends of dynamic
microtubules [42]. This implies that after spastin severing,
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microtubule fragments might be unable to grow due to
fidgetin action (see Table 2 for complete list of proteins
possibly involved in AD and HSP related microtubule dis-
ruption. Considering (i) the past failures of clinical trials on
AD with microtubule stabilizing drugs, (ii) the possible gain
of function mechanisms in HSP, and (iii) the possible detri-
mental action of spastin and fidgetin, it becomes clear that
we need a better understanding of microtubule dynamics in
neurodegeneration. A molecular toolbox of small molecule
inhibitors of microtubule severing enzymes would serve the
further investigation of pathomechanisms in AD, related
tauopathies and HSP, and facilitate the development of new
MT-based therapeutics.
Conclusion
A key result is the identification of a novel reaction cascade
implicated in the missorting of the Tau protein in neurons
affected by AD. The results reveal a multi-step pathway
leading from the exposure of neurons to Aβ oligomers
towards Tau-dependent spine loss and synaptic deficits. We
identified new contributors and functions in the patho-
logical cascade of AD, centered around missorting of Tau
into the somatodendritic compartment. Missorting of Tau
causes the loss of dendritic microtubules mediated by
TTLL6 and spastin. The reaction cascade provides an
explanation for the well-known reduction of microtubules
in AD and might contribute to neurodegeneration in other
Tau-dependent pathological states. Downregulation of spas-
tin prevents loss of microtubules and missorting of Tau,
two key events in Alzheimer pathology. This indicates that
spastin or upstream regulators of spastin activity could
serve as therapeutic targets for AD and related tauopathies.
Moreover, in HSP the pathological gain of function of spas-
tin could be counteracted by targeting the upstream mech-
anism of spastin recruitment to microtubules, i.e. (i) by
inhibiting polyglutamylation by TTLLs or (ii) by increasing
the deglutamylation by CCPs, or (iii) by targeting the bind-
ing of spastin to microtubules. Future studies will have to
show whether microtubule stabilizers, Notch activators,
spastin inhibitors, or its upstream regulators have thera-
peutic value for AD and HSP.
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Table 2 Proteins possibly involved in microtubule breakdown after Aβ insult
Protein (gene name) Physiological function Pathological function Genetic loci [12]
Tau (MAPT) microtubule stabilization, axonal outgrowth aberrant transport of proteins (e.g. TTLL6, fyn),
f-actin dissassembly
17q21.31
TTLL6 (TTLL6) polyGlu chain elongation, preferentially at
α-tubulin
excessive polyglutamylation leading to
aberrant spastin activation
17q21.32
spastin (SPAST) microtubule dynamics, transport of membrane
vesicles/endosomes, dendrite branching
microtubule breakdown 2p22.3
MARK1,2,3,4 (MARK1,2,3,4) transport regulation via phosphorylation of MAPs aberrant phosphorylation of MAPs resulting





TTLL11 (TTLL11) polyGlu chain elongation, preferentially at
α-tubulin
similar action as TTLL6 (but path. role not yet shown) 9q33.2
TTLL1 (TTLL1) polyGlu chain initiation at α- and β- tubulin required for action of TTLL6 and TTLL11




remove (poly)glutamate side chains from
microtubules
impaired function could result in increased





Katanin (KATNA1) microtubule severing, axon branching also activated by polyglutamylation of microtubules
(but path. role not yet shown)
6q24.3
Fidgetin (FIGN) microtubule severing, mitosis regulation path. role not shown 2q24.3
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